Regression of abdominal aortic aneurysm by inhibition of c‐Jun N‐terminal kinase in mice

K Yoshimura, H Aoki, Y Ikeda, A Furutani… - Annals of the New …, 2006 - Wiley Online Library
Abdominal aortic aneurysm (AAA) is a common disease that, when surgical treatment is
inapplicable, results in rupture of the aorta with high mortality. Although nonsurgical …

Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase

K Yoshimura, H Aoki, Y Ikeda, K Fujii, N Akiyama… - Nature medicine, 2005 - nature.com
Abdominal aortic aneurysm (AAA) is a common disease among elderly people that, when
surgical treatment is inapplicable, results in progressive expansion and rupture of the aorta …

Identification of c‐Jun N‐terminal kinase as a therapeutic target for abdominal aortic aneurysm

K Yoshimura, H Aoki, Y Ikeda, A Furutani… - Annals of the New …, 2006 - Wiley Online Library
Despite the advances in molecular cell biology, identification of a therapeutic target in a
given disease still poses a significant challenge. Here we report a strategy for identification …

Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy

H Aoki, K Yoshimura, M Matsuzaki - Journal of Molecular Medicine, 2007 - Springer
Abdominal aortic aneurysm (AAA) is a common disease that causes progressive expansion
and rupture of the aorta with high mortality. There is a large and unmet need for nonsurgical …

Recent advances in pharmacotherapy development for abdominal aortic aneurysm

K Yoshimura, H Aoki - International Journal of Vascular …, 2012 - Wiley Online Library
Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and
rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a …

[HTML][HTML] c‑Jun/Ap‑1 is upregulated in an Ang II‑induced abdominal aortic aneurysm formation model and mediates Chop expression in mouse aortic smooth muscle …

D Sun, M Zhang, Y Li, S Mei… - Molecular Medicine …, 2019 - spandidos-publications.com
Abdominal aortic aneurysm (AAA) is an asymptomatic, potentially lethal disease whose
ruptures have a high mortality rate. An effective pharmacological approach to decrease …

[HTML][HTML] Pravastatin activates activator protein 2 alpha to augment the angiotensin II-induced abdominal aortic aneurysms

H Ma, WJ Liang, MR Shan, XQ Wang, SN Zhou… - Oncotarget, 2017 - ncbi.nlm.nih.gov
We have previously reported that activation of AMP-activated kinase alpha 2 (AMPKa2) by
nicotine or angiotensin II (AngII) instigates formation of abdominal aortic aneurysms (AAA) in …

[HTML][HTML] Genetically engineered resistance for MMP collagenases promotes abdominal aortic aneurysm formation in mice infused with angiotensin II

J Deguchi, H Huang, P Libby, E Aikawa… - Laboratory …, 2009 - Elsevier
Clinical evidence links increased aortic collagen content and stiffness to abdominal aortic
aneurysm (AAA) formation. However, the possibility that excess collagen contributes to AAA …

Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm

PD DiMusto, G Lu, A Ghosh, KJ Roelofs… - Journal of Surgical …, 2012 - Elsevier
BACKGROUND: In humans, there is a 4: 1 male: female ratio in the incidence of abdominal
aortic aneurysms (AAAs). c-Jun-N-terminal kinase (JNK) is an important upstream regulator …

[HTML][HTML] Colchicine protects against the development of experimental abdominal aortic aneurysm

Y Zhao, QR Shen, YX Chen, Y Shi, WB Wu… - Clinical Science …, 2023 - ncbi.nlm.nih.gov
Abdominal aortic aneurysm (AAA) is characterized by at least 1.5-fold enlargement of the
infrarenal aorta, a ruptured AAA is life-threatening. Colchicine is a medicine used to treat …